Genetic engineering CAR-NK cells to express the chemokine receptor CXCR4 has resulted in increased migration toward CXCL12/SDF-1α and enhanced in vivo efficacy against CXCL12/SDF-1α-secreting glioblastoma model U-87 [185]. This evidence concerns the gene CXCL12 and glioblastoma.